Alnylam Pharmaceuticals
ALNY
#722
Rank
$23.55 B
Marketcap
$189.74
Share price
-0.36%
Change (1 day)
15.82%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of March 2023 (TTM): 22.7

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 22.7031. At the end of 2022 the company had a P/S ratio of 25.0.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2022

PS ratio at the end of each year

Year P/S ratio Change
202225.04.08%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
3.35-85.24%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
2.56-88.73%๐Ÿ‡ซ๐Ÿ‡ท France
6.75-70.28%๐Ÿ‡บ๐Ÿ‡ธ USA
12.2-46.37%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
1.02-95.53%๐Ÿ‡บ๐Ÿ‡ธ USA
0.6499-97.14%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
9.23-59.34%๐Ÿ‡บ๐Ÿ‡ธ USA